Emory University Hospital was recently selected as the first medical center to adopt the Liberty endovascular robotic system, developed by Microbot Medical and granted 510(k) clea ...

A clinical trial of adjuvant intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa ...

Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.

Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer. To better understand the potential clinical implications of ...